Verrica Appoints Neetu Dhaliwal as Vice President of Business Development

August 15, 2018 6:50am

WEST CHESTER, Pa., Aug. 15, 2018 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced the appointment of Neetu Dhaliwal as Vice President of Business Development.

“We are very pleased to have Neetu join our team at this pivotal time in the company’s development,” commented Ted White, President and Chief Executive Officer of Verrica. “Neetu, as a member of the PBM Capital team, has worked with Verrica for the last 7 months, helping us complete a successful Series C Raise and IPO. Neetu will be collaborating with physicians and academic centers to find and help develop unique therapeutic options in dermatology.”

Neetu Dhaliwal joins Verrica after a decade on Wall Street in healthcare investing, most recently with PBM Capital Group, LLC, Verrica’s initial institutional investor. She began her career at J.P. Morgan in Healthcare Investment Banking. Neetu received a B.S in Economics with a Concentration in Finance from The Wharton School, University of Pennsylvania.

About Verrica Pharmaceuticals Inc.

Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential clinical development of Verrica’s product candidates and the availability of data from Verrica’s clinical trials. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Verrica’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Verrica’s prospectus filed with the U.S. Securities and Exchange Commission (SEC) pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on June 15, 2018 and Verrica’s other Periodic Reports filed with the SEC.  Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.



Terry Kohler 
Chief Financial Officer

Kevin Gardner
LifeSci Advisors

Chris Calabrese
LifeSci Advisors


Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum

October 11th, 2023 | 11:00 AM ET